At a glance
- Originator Shionogi
- Class Antineoplastics; Hydroxamic acids
- Mechanism of Action Transcription factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 Jun 1998 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 02 Oct 1996 Preclinical development for Cancer in Japan (Unknown route)